C 末端α-1-抗胰蛋白酶肽作为危重症 COVID-19 患者医院死亡率的新型预测指标 - Suppr | 超能文献

C-terminal alpha-1-antitrypsin peptides as novel predictor of hospital mortality in critically ill COVID-19 patients.

作者信息

Scherr Franziska, Schwarzkopf Daniel, Thomas-Rüddel Daniel, Bauer Michael, Kiehntopf Michael

机构信息

Institute of Clinical Chemistry and Laboratory Diagnostics, Jena University Hospital, Jena, Germany.

Department of Anaesthesiology and Intensive Care Medicine, Jena University Hospital, Jena, Germany.

出版信息

Clin Chem Lab Med. 2024 Aug 19;63(3):e78-e81. doi: 10.1515/cclm-2024-0920. Print 2025 Feb 25.

DOI:10.1515/cclm-2024-0920

Abstract

摘要

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

文档翻译

学术文献翻译模型，支持多种主流文档格式。

相似文献

1

C-terminal alpha-1-antitrypsin peptides as novel predictor of hospital mortality in critically ill COVID-19 patients.C 末端α-1-抗胰蛋白酶肽作为危重症 COVID-19 患者医院死亡率的新型预测指标

Clin Chem Lab Med. 2024 Aug 19;63(3):e78-e81. doi: 10.1515/cclm-2024-0920. Print 2025 Feb 25.

2

Imbalance between alpha-1-antitrypsin and interleukin 6 is associated with in-hospital mortality and thrombosis during COVID-19.α1-抗胰蛋白酶与白细胞介素 6 失衡与 COVID-19 住院期间的死亡率和血栓形成有关。

Biochimie. 2022 Nov;202:206-211. doi: 10.1016/j.biochi.2022.07.012. Epub 2022 Aug 8.

3

Host genomics of COVID-19: Evidence point towards Alpha 1 antitrypsin deficiency as a putative risk factor for higher mortality rate.新冠病毒宿主基因组学：有证据表明，α1 抗胰蛋白酶缺乏症可能是导致更高死亡率的一个潜在危险因素。

Med Hypotheses. 2021 Feb;147:110485. doi: 10.1016/j.mehy.2021.110485. Epub 2021 Jan 9.

4

Two peptides released in the complex formation of alpha 1-antitrypsin with beta-trypsin; evidence for two structurally identical, inhibitory sites in alpha 1-antitrypsin.在α1-抗胰蛋白酶与β-胰蛋白酶形成复合物的过程中释放出的两种肽；α1-抗胰蛋白酶中存在两个结构相同的抑制位点的证据。

Int J Pept Protein Res. 1982 Aug;20(2):126-32. doi: 10.1111/j.1399-3011.1982.tb02664.x.

5

A Prognostic Model for In-Hospital Mortality in Critically Ill Patients with Pneumonia.重症肺炎患者院内死亡的预测模型

Infect Drug Resist. 2022 Nov 2;15:6441-6450. doi: 10.2147/IDR.S377411. eCollection 2022.

6

Does hypersialylation compensate the functional Alpha1-AntiTrypsin (A1AT) deficiency in all critically ill patients?高唾液酸化是否能补偿所有重症患者功能性α1-抗胰蛋白酶（A1AT）缺乏的情况？

Biochimie. 2025 Mar;230:114-120. doi: 10.1016/j.biochi.2024.11.008. Epub 2024 Nov 17.

7

Alpha 1 Antitrypsin Therapy in Patients with Alpha 1 Antitrypsin Deficiency: Perspectives from a Registry Study and Practical Considerations for Self-Administration During the COVID-19 Pandemic.抗胰蛋白酶缺乏症患者的 Alpha 1 抗胰蛋白酶治疗：来自注册研究的观点和 COVID-19 大流行期间自我管理的实际考虑。

Int J Chron Obstruct Pulmon Dis. 2021 Nov 1;16:2983-2996. doi: 10.2147/COPD.S325211. eCollection 2021.

8

The reactive site of alpha 1-antitrypsin is C-terminal, not N-terminal.α1-抗胰蛋白酶的反应位点位于C末端，而非N末端。

Biochim Biophys Acta. 1983 Apr 28;744(2):212-8. doi: 10.1016/0167-4838(83)90093-6.

9

Intravenous Alpha-1 Antitrypsin Therapy for Critically Ill COVID-19 Patients.静脉注射α-1抗胰蛋白酶治疗重症COVID-19患者。

Isr Med Assoc J. 2022 Jul;24(7):441-443.

10

Critically Ill . Non-Critically Ill Patients With COVID-19 Pneumonia: Clinical Features, Laboratory Findings, and Prediction.危重症/非危重症 COVID-19 肺炎患者：临床特征、实验室检查结果和预测因素。

Front Cell Infect Microbiol. 2021 Jul 13;11:550456. doi: 10.3389/fcimb.2021.550456. eCollection 2021.

引用本文的文献

1

Alpha-1-antitrypsin as novel substrate for Spl proteases - implications for virulence.α-1-抗胰蛋白酶作为Spl蛋白酶的新型底物——对毒力的影响

Front Immunol. 2024 Nov 19;15:1481181. doi: 10.3389/fimmu.2024.1481181. eCollection 2024.